Marinus Pharmaceuticals Inc expected to post a loss of 70 cents a share - Earnings Preview

Marinus Pharmaceuticals

03/03/2023 22:43

* Marinus Pharmaceuticals Inc  MRNS.OQ   MRNS.O  is expected
to show a rise in quarterly revenue when it reports  results on
March 7. 
    * The Radnor Pennsylvania-based  company is expected to
report  a
252.1% increase in revenue to $5.352 million from $1.52 million
a year ago, according to the mean estimate from 9 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Marinus
Pharmaceuticals
Inc is for a loss of 70 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 10 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Marinus
Pharmaceuticals Inc is $23​, above​ its last closing price
of $6.73. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  0.54        0.47       -0.94     Missed  -301.2
 Jun. 30 2022  -0.64       -0.69      -1.06     Missed  -54.7
 Mar. 31 2022  -0.85       -0.85      -0.52     Beat    38.8​
 Dec. 31 2021  -0.72       -0.76      -0.77     Missed  -1.2
 ​​Sep.        -0.73       -0.73      -0.53     Beat    27.6
 30 2021                                                
 Jun. 30 2021  -0.69       -0.69      -0.65     Beat    5.3​
 Mar. 31 2021  -0.45       -0.45      -0.74     Missed  -63.9
 Dec. 31 2020  -0.50       -0.51      -0.55     Missed  -8.6
 This summary was machine generated March 3 at 22:43 GMT.  All
figures in US dollars  unless otherwise stated